15th Drug Discovery Summit

250 delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions

55 presentations, case studies and panel discussions focused on the key issues in drug discovery and medicinal chemistry

6 Interactive Streams:

• Target Based Discovery
• Screening & Assays: Enabling Technologies
• Preclinical Biomarkers and Translational Medicine
• Supporting Innovation: Data & Information Management
• Discovery Chemistry: Latest Case Studies
• Drug Design: Novel Approaches

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Oxford Global Conferences are proud to present the 16th Annual Drug Discovery Leaders Summit, taking place on the 8th and 9th of June in Berlin. This summit brings together a host of senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve drug discovery going forward.

The discovery landscape has  shifted over the past few years – we have seen the resurgence of phenotypic screening, the shift from high throughput screening to high content analysis, novel applications of genomic technologies and a renewed emphasis on the role of collaboration and open innovation models.  We are also seeing an increased focus on strengthening data and knowledge management in R&D pipelines to make the most of discovery data, with researchers seeking new techniques to manage complex early stage discovery portfolios and for library optimisation.

In addition to exploring the trends outlined above, our speakers will tackle current debates in the industry such as the value of phenotypic screening over target-based screening, finding physiologically relevant screen models using 3D models and iPSC, and new methods to target GPCRs and ion channels. Presentations will also cover assays in human tissues and biopsies, as well as the latest innovations in discovery technology including NMR screening platforms, live cell imaging and improved biomarkers to reduce drug attrition.

For the past two years our Discovery Chemistry & Drug Design Congress has proved a popular addition to the summit. This year our Congress will feature key discovery chemistry case studies, including novel tools for PPI targeting such as NMR and SPR. Presentations will also cover novel computational tools for drug design, DMPK considerations in lead optimisation and how to build increasing molecular complexity into drug design.